返回
摘要
En 中文
Those who have followed the gene-therapy field over the decades may be weary of forward-looking positive statements. However, over the past 3 years, six gene-therapy products have been approved for clinical use. This article describes challenges, risks, and advances in gene-therapy clinical research.
Keyword:
SEVERE COMBINED IMMUNODEFICIENCY
LONG-TERM SAFETY
FACTOR-IX
RETROVIRAL VECTORS
CANINE MODEL
OPEN-LABEL
CELL
HEMOPHILIA
EFFICACY
ACTIVATION
AI总结
对已上传原文的论文进行重点信息的提取,主要内容包括:简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
78.5
论文数:
2.7W
被引数:
44.4W
机构
引用论文
A “pennurth of arsenic for rat poison”: The Arsenic Act, 1851 and the prevention of secret poisoning
Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trialvoretigene neparvovec (AAV2-hRPE65v2) 在RPE65-mediated遗传性视网膜营养不良患者中的疗效和安全性: 一项随机,对照,开放标签的3期试验
LANCET
IF88.5

